BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 31977852)

  • 1. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
    Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
    Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
    Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study.
    Wang Y; Hu X; Xu W; Wang H; Huang Y; Che G
    Thorac Cancer; 2019 Jun; 10(6):1402-1411. PubMed ID: 31104359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
    Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
    Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
    Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
    J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma.
    Yapar A; Tokgöz MA; Yapar D; Atalay İB; Ulucaköy C; Güngör BŞ
    Jt Dis Relat Surg; 2021; 32(2):489-496. PubMed ID: 34145828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang Y; Jiang C; Li J; Sun J; Qu X
    Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
    Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M
    PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
    Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
    Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
    Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
    Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive values of the postoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio for the diagnosis of early periprosthetic joint infections: a preliminary study.
    Zhao G; Chen J; Wang J; Wang S; Xia J; Wei Y; Wu J; Huang G; Chen F; Shi J; Lyu J; Liu C; Huang X
    J Orthop Surg Res; 2020 Nov; 15(1):571. PubMed ID: 33256763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.
    Yu J; Huang L; Dong T; Cao L
    J Obstet Gynaecol; 2024 Dec; 44(1):2361858. PubMed ID: 38864403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer.
    Cheng H; Bhushan S; Li N; Xiao Z; Gao K
    J Cancer Res Ther; 2022; 18(6):1666-1673. PubMed ID: 36412428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.